Study of brain recurrence risk in HER2-positive breast cancer
Part of Cancer clinical trials.
This study looks at women with HER2-positive breast cancer who will get chemotherapy before surgery. The goal is to find out what factors might increase the chance of the cancer spreading to the brain later on.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You are a woman
- You have breast cancer that is HER2-positive (a type that can be treated with targeted therapy)
- Your treatment plan includes chemotherapy before surgery, and a small clip has been placed in the tumor during biopsy
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks the brain using MRI in people with breast cancer that has spread outside the breast or can’t be fully removed. The goal is to screen for brain involvement and see how MRI findings fit with treatment timing, when it’s safe to do so.
This trial checks whether taking screening brain MRI scans in people with stage IV breast cancer helps find brain involvement earlier. It may help guide treatment decisions for those who would otherwise only get brain imaging after symptoms start.
This trial tests a combination of targeted drugs (Initumab and Pyrrotinib) plus chemotherapy before surgery for HER2-positive breast cancer. It compares different treatment lengths to see which is more effective and safe.
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
This study is testing regular MRI brain scans to find any brain metastases early in people with HER2-positive breast cancer that has spread. It aims to see if early detection can help guide treatment and improve outcomes.
This study tests whether regular brain scans (surveillance) help spot brain metastases early in people with HER2-positive breast cancer that has spread to other parts of the body. Participation involves being randomly assigned to either routine brain scans or no extra scans to see which approach is better.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.